Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-canonical miRNA-RNA base-pairing impedes tumor suppressor activity of miR-16.
Quéméner AM, Bachelot L, Aubry M, Avner S, Leclerc D, Salbert G, Cabillic F, Decaudin D, Mari B, Mouriaux F, Galibert MD, Gilot D. Quéméner AM, et al. Among authors: decaudin d. Life Sci Alliance. 2022 Oct 6;5(12):e202201643. doi: 10.26508/lsa.202201643. Life Sci Alliance. 2022. PMID: 36202613 Free PMC article.
Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].
Decaudin D, Dit Leitz EF, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S. Decaudin D, et al. Eur J Cancer. 2023 May;184:199. doi: 10.1016/j.ejca.2023.02.004. Epub 2023 Mar 1. Eur J Cancer. 2023. PMID: 36868971 Free article. No abstract available.
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Ducarouge B, Redavid AR, Victoor C, Chira R, Fonseca A, Hervieu M, Bergé R, Lengrand J, Vieugué P, Neves D, Goddard I, Richaud M, Laval PA, Rama N, Goldschneider D, Paradisi A, Gourdin N, Chabaud S, Treilleux I, Gadot N, Ray-Coquard I, Depil S, Decaudin D, Némati F, Marangoni E, Mery-Lamarche E, Génestie C, Tabone-Eglinger S, Devouassoux-Shisheboran M, Moore KJ, Gibert B, Mehlen P, Bernet A. Ducarouge B, et al. Among authors: decaudin d. Cell Death Differ. 2023 Oct;30(10):2201-2212. doi: 10.1038/s41418-023-01209-x. Epub 2023 Aug 26. Cell Death Differ. 2023. PMID: 37633969
Ophthalmologic and intraocular non-Hodgkin's lymphoma: a large single centre study of initial characteristics, natural history, and prognostic factors.
Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A, Dendale R, Asselain B, Arnaud P, Fourquet A, Desjardins L, Plancher C, Validire P, Chaoui D, Lévy C, Decaudin D. Meunier J, et al. Among authors: decaudin d. Hematol Oncol. 2004 Dec;22(4):143-58. doi: 10.1002/hon.741. Hematol Oncol. 2004. PMID: 16134191 Review.
Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors.
Meunier J, Lumbroso-Le Rouïc L, Dendale R, Vincent-Salomon A, Asselain B, Arnaud P, Némati F, Fourquet A, Desjardins L, Plancher C, Levy C, Chaoui D, Validire P, Decaudin D. Meunier J, et al. Among authors: decaudin d. Leuk Lymphoma. 2006 Jul;47(7):1295-305. doi: 10.1080/10428190500518966. Leuk Lymphoma. 2006. PMID: 16923560
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, Camonis J, Desjardins L, Cassoux N, Piperno-Neumann S, Mariani P, Sastre X, Decaudin D, Roman-Roman S. Amirouchene-Angelozzi N, et al. Among authors: decaudin d. Mol Oncol. 2014 Dec;8(8):1508-20. doi: 10.1016/j.molonc.2014.06.004. Epub 2014 Jun 13. Mol Oncol. 2014. PMID: 24994677 Free PMC article.
163 results